Scorpion Therapeutics Appoints Adam Friedman as Chief Executive Officer
Scorpion Therapeutics is entering its “next phase of growth” in 2024, leaving former CEO Axel Hoos, M.D., Ph.D., and ex-Chief Medical Officer Michael Streit, M.D., behind.
Scorpion Appoints Precision Medicine Leader Jeff Albers as Strategic Advisor
Scorpion Therapeutics Presents Preclinical Data for STX-241, a Fourth-Generation EGFR Inhibitor, at the AACR-NCI-EORTC Symposium 2023
French pharma Pierre Fabre is offering up to $553 million in biobucks to work with Scorpion Therapeutics on developing and potentially commercializing two of the biotech’s preclinical lung cancer candidates.
Scorpion Therapeutics Nominates STX-241 as Potentially Best-in-Class Fourth-Generation EGFR Inhibitor Development Candidate for the Treatment of Non-Small Cell Lung Cancer
Scorpion Therapeutics Presents Preclinical Data for Potential Best-in-Class PI3K? Inhibitor at San Antonio Breast Cancer Symposium